Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Walid Abi-Saab"'
Autor:
Kevin K Brown, Toby M Maher, Michael Kreuter, David J Lederer, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi-Saab, Marlies Wijsenbeek
Publikováno v:
BMJ Open Respiratory Research, Vol 6, Iss 1 (2019)
Introduction While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improv
Externí odkaz:
https://doaj.org/article/13f5f55143134d038a4aea43947c04e4
Autor:
Michael Kreuter, Ann Fieuw, Paul Ford, Marlies S. Wijsenbeek, Simone Stutvoet, Nadia Verbruggen, David J. Lederer, Wim A. Wuyts, Toby M. Maher, Walid Abi-Saab, Kevin K. Brown
Publikováno v:
BMJ Open Respiratory Research
BMJ Open Respiratory Research, 6(1):UNSP e000422. BMJ Publishing Group
BMJ Open Respiratory Research, 6(1):UNSP e000422. BMJ Publishing Group
IntroductionWhile current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve
Autor:
R. Besuyen, Philip J. Mease, Dafna D. Gladman, Chantal Tasset, L. Meuleners, Laura C. Coates, Annegret Van der Aa, Rebecca Kunder, Anna Dudek, Joy M Greer, Mykola Stanislavchuk, Philip S. Helliwell, Filip Van den Bosch, P. Harrison, Neelufar Mozaffarian, Anna Rychlewska-Hanczewska, Walid Abi-Saab
The Janus kinase 1 (JAK1) pathway has been implicated in the pathogenesis of psoriatic arthritis. We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis.The EQUATOR trial wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad0982792732d2fb545eaab72d2dd14
https://ora.ox.ac.uk/objects/uuid:4edadb75-917f-4a51-a319-707d56c296b3
https://ora.ox.ac.uk/objects/uuid:4edadb75-917f-4a51-a319-707d56c296b3
Autor:
Joy M Greer, Désirée van der Heijde, Xenofon Baraliakos, Robert Landewé, Atul Deodhar, R. Besuyen, Vira Tseluyko, Ke Liu, Chantal Tasset, Neelufar Mozaffarian, Oleg Nadashkevich, Lianne S. Gensler, Walter P. Maksymowych, Walid Abi-Saab, Thijs Hendrikx, L. Meuleners
Publikováno v:
Lancet, 392(10162), 2378-2387. Elsevier Limited
Lancet, 392(10162), 2378-2387
van der Heijde, Desiree; Baraliakos, Xenofon; Gensler, Lianne S; Maksymowych, Walter P; Tseluyko, Vira; Nadashkevich, Oleg; et al.(2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. LANCET, 392(10162), 2378-2387. doi: 10.1016/S0140-6736(18)32463-2. UCSF: Retrieved from: http://www.escholarship.org/uc/item/98d1m6ss
Lancet (London, England), vol 392, iss 10162
Lancet, 392(10162), 2378-2387
van der Heijde, Desiree; Baraliakos, Xenofon; Gensler, Lianne S; Maksymowych, Walter P; Tseluyko, Vira; Nadashkevich, Oleg; et al.(2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. LANCET, 392(10162), 2378-2387. doi: 10.1016/S0140-6736(18)32463-2. UCSF: Retrieved from: http://www.escholarship.org/uc/item/98d1m6ss
Lancet (London, England), vol 392, iss 10162
Background: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da183d252b0c8f754544114f22f4aab6
https://pure.amc.nl/en/publications/efficacy-and-safety-of-filgotinib-a-selective-janus-kinase-1-inhibitor-in-patients-with-active-ankylosing-spondylitis-tortuga-results-from-a-randomised-placebocontrolled-phase-2-trial(9caabb31-05ba-4906-acd4-a15c22e7e725).html
https://pure.amc.nl/en/publications/efficacy-and-safety-of-filgotinib-a-selective-janus-kinase-1-inhibitor-in-patients-with-active-ankylosing-spondylitis-tortuga-results-from-a-randomised-placebocontrolled-phase-2-trial(9caabb31-05ba-4906-acd4-a15c22e7e725).html
Publikováno v:
American Journal of Hematology. 89:505-508
MRI relaxometry (R2, R2*) has generally replaced liver biopsy for estimation of liver iron stores in response to iron chelation, but there have been no longitudinal studies comparing R2 and R2* techniques. We use R2 and R2* liver iron concentration (
Autor:
Yili Pritchett, George Apostol, Walid Abi-Saab, James J. McGough, Mario D. Saltarelli, Weining Z. Robieson, Earle E. Bain, Tushar S. Garimella
Publikováno v:
Neuropsychopharmacology. 38:405-413
Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, d
Publikováno v:
Magnetic resonance imaging. 33(6)
Purpose Liver biopsy was long considered the reference standard for measuring liver iron concentration. However, its high sampling variability and invasive nature make it poorly suited for serial analyses. To demonstrate the fallibility of liver biop
Publikováno v:
American journal of hematology. 89(5)
MRI relaxometry (R2, R2*) has generally replaced liver biopsy for estimation of liver iron stores in response to iron chelation, but there have been no longitudinal studies comparing R2 and R2* techniques. We use R2 and R2* liver iron concentration (
Autor:
George, Apostol, Walid, Abi-Saab, Christopher J, Kratochvil, Lenard A, Adler, Weining Z, Robieson, Laura M, Gault, Yili L, Pritchett, David, Feifel, Michelle A, Collins, Mario D, Saltarelli
Publikováno v:
Psychopharmacology. 219(3)
α(4)β(2) Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD).This study examined the efficacy and safety of the α(4)β(2) NNR partial agonist ABT-089 versus placebo in adults
Autor:
Laura, Redden, Melissa, DelBello, Karen Dineen, Wagner, Timothy E, Wilens, Shishuka, Malhotra, Patricia, Wozniak, Namita V, Vigna, Nicholas, Greco, Xenia, Kovacs, Walid, Abi-Saab, Mario, Saltarelli, Juanita Lynn, Taylor
Publikováno v:
Journal of child and adolescent psychopharmacology. 19(1)
The objective of this open-label study was to assess the safety of divalproex sodium extended-release in the treatment of children and adolescents with acute mania associated with bipolar I disorder.This was a 6-month, Phase 3, open-label study in he